Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Radiol Oncol. 2014 Apr 25;48(2):155-62. doi: 10.2478/raon-2013-0072. eCollection 2014 Jun.
Clonality determination in patients with lymphoproliferative disorders can improve the final diagnosis. The aim of our study was to evaluate the applicative value of standardized BIOMED-2 gene clonality assay protocols for the analysis of clonality of lymphocytes in a group of different lymphoid proliferations.
With this purpose, 121 specimens from 91 patients with suspected lymphoproliferations submitted for routine diagnostics from January to December 2011 were retrospectively analyzed. According to the final diagnosis, our series comprised 32 cases of B-cell lymphomas, 38 cases of non-Hodgkin's T-cell lymphomas and 51 cases of reactive lymphoid proliferations. Clonality testing was performed using the BIOMED-2 clonality assays.
The determined sensitivity of the TCR assay was 91.9%, while the sensitivity of the IGH assay was 74.2%. The determined specificity of the IGH assay was 73.3% in the group of lymphomas and 87.2% in the group of reactive lesions. The determined specificity of the TCR assay was 62.5% in the group of lymphomas and 54.3% in the group of reactive lesions.
In the present study, we confirmed the utility of standardized BIOMED-2 clonality assays for the detection of clonality in a routine diagnostical setting of non-Hodgkin's lymphomas. Reactions for the detection of the complete IGH rearrangements and reactions for the detection of the TCR rearrangements are a good choice for clonality testing of a wide range of lymphoid proliferations and specimen types while the reactions for the detection of incomplete IGH rearrangements have not shown any additional diagnostic value.
在淋巴增生性疾病患者中进行克隆性确定可以改善最终诊断。我们研究的目的是评估标准化 BIOMED-2 基因克隆性检测方案在一组不同的淋巴增生中的淋巴细胞克隆性分析中的应用价值。
为此,我们回顾性分析了 2011 年 1 月至 12 月间因疑似淋巴增生而送检常规诊断的 91 例患者的 121 份标本。根据最终诊断,我们的系列包括 32 例 B 细胞淋巴瘤、38 例非霍奇金 T 细胞淋巴瘤和 51 例反应性淋巴增生。使用 BIOMED-2 克隆性检测进行克隆性检测。
TCR 检测的确定敏感性为 91.9%,而 IGH 检测的敏感性为 74.2%。在淋巴瘤组中,IGH 检测的确定特异性为 73.3%,在反应性病变组中为 87.2%。在淋巴瘤组中,TCR 检测的确定特异性为 62.5%,在反应性病变组中为 54.3%。
在本研究中,我们证实了标准化 BIOMED-2 克隆性检测方案在非霍奇金淋巴瘤常规诊断中的实用性。用于检测完整 IGH 重排的反应和用于检测 TCR 重排的反应是检测广泛的淋巴增生和标本类型的克隆性的良好选择,而用于检测不完全 IGH 重排的反应没有显示出任何额外的诊断价值。